- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Forte Biosciences Prices $150M Public Offering
Biotech firm raises significant capital to fund growth initiatives.
Apr. 9, 2026 at 3:10am
Got story updates? Submit your updates here. ›
Forte Biosciences' $150 million public offering signals the biotech industry's continued strength and investor confidence in innovative drug development.Dallas TodayForte Biosciences, a clinical-stage biopharmaceutical company, has announced the pricing of its $150 million public offering. The company plans to use the proceeds to advance its pipeline of innovative therapies and support ongoing research and development efforts.
Why it matters
This public offering represents a major milestone for Forte Biosciences, providing the company with substantial capital to accelerate its growth and further develop its promising drug candidates. The successful fundraising is a positive sign for the biotech industry, which has seen increased investor interest amid the COVID-19 pandemic.
The details
Forte Biosciences priced its public offering of 10 million shares of common stock at $15 per share. The company has also granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares at the same price. The offering is expected to close on April 13, 2026, subject to customary closing conditions.
- The public offering was priced on April 8, 2026.
- The offering is expected to close on April 13, 2026.
The players
Forte Biosciences
A clinical-stage biopharmaceutical company focused on developing innovative therapies to treat a variety of medical conditions.
What they’re saying
“This public offering represents a significant milestone for Forte Biosciences and will provide us with the resources to accelerate the development of our pipeline and bring our therapies to patients in need.”
— Paul Little, Chief Executive Officer, Forte Biosciences
What’s next
Forte Biosciences expects to use the proceeds from the offering to advance its clinical programs, expand its research and development efforts, and for general corporate purposes.
The takeaway
Forte Biosciences' successful $150 million public offering highlights the continued investor appetite for promising biotech companies with innovative drug candidates in their pipelines. The additional capital will enable the company to further its growth and development initiatives, positioning it for potential future success.
